Ovid Therapeutics Inc (OVID)

Jun 15, 2026

OVID: Multiple clinical milestones and strong financial runway position the pipeline for significant value creation - TradingView

Jun 15, 2026

Jun 11, 2026

Ovid Therapeutics (OVID) Slips 1.97% as Shares Test Key Support LevelsStrong Buy Stocks - newsline.com

Jun 11, 2026

Jun 11, 2026

Ovid Therapeutics Shareholders Back Board and Governance Proposals - TipRanks

Jun 11, 2026

Jun 11, 2026

Ovid Therapeutics (NASDAQ: OVID) shareholders approve director, pay and auditor - Stock Titan

Jun 11, 2026

Jun 10, 2026

Ovid Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 10, 2026

Jun 04, 2026

Ovid Board Move Puts Scientific Strategy Back In Focus - Kalkine Media

Jun 04, 2026

Jun 04, 2026

Ovid Therapeutics Expands Board, Appoints New Scientific Director - The Globe and Mail

Jun 04, 2026

Jun 04, 2026

Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Jun 04, 2026

Jun 04, 2026

Ovid Therapeutics appoints Anna Greka to board of directors - Investing.com UK

Jun 04, 2026

Jun 04, 2026

Biotech Ovid Therapeutics joins June neuro investor conferences - Stock Titan

Jun 04, 2026

Jun 03, 2026

Ovid Therapeutics appoints Anna Greka to board of directors By Investing.com - Investing.com Canada

Jun 03, 2026

Jun 03, 2026

Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven - Stock Titan

Jun 03, 2026

Jun 03, 2026

Press Release: Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors - Moomoo

Jun 03, 2026

Jun 01, 2026

OVIDOvid Therapeutics Inc Stock Price and Quote - Finviz

Jun 01, 2026

May 28, 2026

Ovid Therapeutics (OVID) Gains Nearly 4% as Shares Test Key ResistanceDynamic Hedging - newsline.com

May 28, 2026

May 27, 2026

Will Ovid’s golden age of KCC2 metamorph CNS? - BioWorld News

May 27, 2026

May 26, 2026

H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4 - Moomoo

May 26, 2026

May 19, 2026

OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

May 19, 2026

May 15, 2026

Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan

May 15, 2026

May 15, 2026

Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan

May 15, 2026

May 15, 2026

Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan

May 15, 2026

May 15, 2026

Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan

May 15, 2026

May 14, 2026

[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan

May 14, 2026

May 14, 2026

Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan

May 14, 2026

May 14, 2026

We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance

May 14, 2026

May 13, 2026

Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo

May 13, 2026

May 13, 2026

LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo

May 13, 2026

May 13, 2026

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia

May 13, 2026

May 13, 2026

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India

May 13, 2026

May 13, 2026

TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo

May 13, 2026

May 12, 2026

Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo

May 12, 2026

May 12, 2026

William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo

May 12, 2026

May 12, 2026

Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada

May 12, 2026

May 12, 2026

OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus

May 12, 2026

May 12, 2026

Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 12, 2026

May 12, 2026

Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2026

May 12, 2026

Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart

May 12, 2026

May 12, 2026

Ovid Therapeutics stock rises 4% on in-line results, pipeline progress By Investing.com - Investing.com South Africa

May 12, 2026

May 12, 2026

Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com UK

May 12, 2026

May 12, 2026

OVID: Advancing novel therapies for seizures and psychosis with strong safety and market potential - TradingView

May 12, 2026

May 12, 2026

Ovid Therapeutics : May 2026 Corporate Presentation - marketscreener.com

May 12, 2026

May 12, 2026

Ovid Therapeutics Q1 net loss widens as R&D spending rises - TradingView

May 12, 2026

May 12, 2026

Ovid Therapeutics Inc. 1Q 2026: Revenue $0M, Net loss $17M, EPS $(0.12) — 10-Q Summary - TradingView

May 12, 2026

May 12, 2026

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times

May 12, 2026

May 12, 2026

Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 12, 2026

May 12, 2026

Ovid Therapeutics (NASDAQ: OVID) widens Q1 loss but boosts cash to $165.6M - Stock Titan

May 12, 2026

May 12, 2026

Ovid Therapeutics (NASDAQ: OVID) extends cash runway into 2029 - Stock Titan

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 10, 2026

Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks - Yahoo Finance

May 10, 2026